Skip to content

Mechanism of the Method of Warming Yang and Dispelling Wind to Regulate the Chronic Ulcerative Colitis with Yang Deficiency and Dampness Stagnation Syndrome through the Crosstalk Between JNK1/2-STAT1 and P38MAKP Signal Pathway Based on Network Pharmacology

Mechanism of the Method of Warming Yang and Dispelling Wind to Regulate the Chronic Ulcerative Colitis with Yang Deficiency and Dampness Stagnation Syndrome through the Crosstalk Between JNK1/2-STAT1 and P38MAKP Signal Pathway Based on Network Pharmacology

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039127
Enrollment
Unknown
Registered
2020-10-17
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic ulcerative colitis

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for healthy subjects: 1. Those aged between 18 and 75 are not limited to men and women; 2. Subjects with BMI between 18 and 26 kg / m2; 3. The subjects who had no previous intestinal diseases and normal stool pattern had no history of using antibiotics and intestinal flora preparations in the past month; 4. The subjects with history of hypertension, heart disease, diabetes, tuberculosis and hepatitis were excluded by physical examination and laboratory examination; 5. The subjects agreed to participate in this study and signed the informed consent form. The informed consent process was in accordance with the quality management rules of drug clinical trials (GCP). Inclusion criteria: Patients with chronic ulcerative colitis 1. Patients with ulcerative colitis diagnosed by western medicine were classified into chronic recurrent type and / or chronic persistent type; 2. Patients with spleen and kidney yang deficiency syndrome, spleen deficiency and dampness accumulation syndrome and large intestine dampness heat syndrome; 3. Patients between 18 and 75 years old, male or female; 4. The patients who agreed to participate in this study were willing to accept the relevant examination and signed the informed consent form. The informed consent process was in line with the quality management rules of drug clinical trials (GCP).

Exclusion criteria

Exclusion criteria: 1. Patients with severe complications, such as toxic megacolon, intestinal obstruction, stenosis, perforation and canceration; 2. Pregnant or lactating women; 3. Patients with serious diseases such as hematopoietic system, liver, kidney and endocrine system; 4. Patients with mental diseases; 5. Patients with suspected or definite history of alcohol or drug abuse; 6. Patients who are using drugs that may affect gastrointestinal function; 7. Patients with allergic history and severe food allergy to the related drugs used in this study; 8. Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Disease severity and patient activity (modified Mayo score);Baron endoscopic score;Gebones index;

Secondary

MeasureTime frame
Individual and overall scores of main symptoms;Symptom and syndrome integral scale of Traditional Chinese Medicine;Blood routine examination;Stool routine examination (+ occult blood test);Liver function examination;Renal function examination;Inflammation index (CXCL8 and ICAM-1);

Countries

China

Contacts

Public ContactZhang Shuxin

Dongzhimen Hospital of Beijing University of traditional Chinese Medicine

zhshxincn@126.com+86 13661027611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026